+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Tests for Alzheimer's Diagnosis Market - Global Forecast to 2030- Product Image
Blood Tests for Alzheimer's Diagnosis Market - Global Forecast to 2030- Product Image
New

Blood Tests for Alzheimer's Diagnosis Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081251
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Blood-based diagnostics for Alzheimer’s disease have emerged as a critical pillar in the quest to improve early detection and patient outcomes. Recent breakthroughs in biomarker research, coupled with advancements in assay technologies, have shifted the paradigm from invasive procedures and delayed symptom recognition toward minimally invasive, rapid testing solutions. Stakeholders across clinical, research and pharmaceutical domains are now evaluating how blood tests can streamline differential diagnosis, monitor disease progression and accelerate therapeutic development.

As the burden of Alzheimer’s continues to grow globally, reliable peripheral biomarkers promise to transform clinical pathways. Clinicians can integrate routine blood screening into primary care workflows, while researchers leverage multiplex assays to identify novel pathological signatures. Meanwhile, pharmaceutical developers can harness predictive testing to stratify trial cohorts more effectively. Together, these innovations not only pave the way for earlier interventions but also unlock new avenues for personalized medicine.

Transformative Shifts Reshaping Alzheimer’s Blood Test Development

Over the past decade, the diagnostic landscape has undergone profound shifts driven by technological innovation, regulatory recalibration and evolving clinical needs. High-sensitivity immunoassays now detect tau and beta-amyloid fragments at femtomolar concentrations, enabling clinicians to discern subtle neurodegenerative changes long before cognitive symptoms manifest. Concurrently, next-generation sequencing platforms have expanded the repertoire of metabolic and genetic markers under investigation, broadening the diagnostic toolkit beyond classical protein targets.

At the same time, point-of-care analyzers have evolved from bulky laboratory prototypes into portable solutions capable of delivering results within minutes. This decentralization of testing empowers community clinics and primary care providers to adopt early screening protocols without reliance on specialized infrastructure. In parallel, multiplex assay technologies-ranging from microarray-based panels to mass spectrometry workflows-support simultaneous quantification of diverse biomarker classes, streamlining research pipelines and accelerating biomarker validation.

These technological strides coincide with a more receptive regulatory environment. Accelerated approval pathways and biomarker qualification programs have reduced time to market for innovative assays, encouraging investment and collaboration between diagnostic developers and academic research centers. Together, these forces are redefining the standard of care in neurodegenerative disease management.

Cumulative Impact of US Tariffs on Alzheimer's Diagnostics Ecosystem

New tariffs slated for implementation in 2025 have introduced additional layers of complexity for manufacturers and distributors of reagents, instruments and consumables. Import duties on high-value components such as monoclonal antibodies, mass spectrometers and microarray chips are projected to elevate production costs. Consequently, diagnostic developers face tighter margins, compelling them to rethink supply chain strategies and explore alternative sourcing or localized manufacturing hubs.

For companies reliant on specialized equipment from Europe or Asia-Pacific, the imposition of cumulative duties has triggered a reassessment of procurement contracts. Some firms are negotiating long-term off-tariff agreements or leveraging free-trade zones to mitigate cost pressures. Others are accelerating efforts to qualify domestic suppliers capable of maintaining stringent quality standards.

Despite these headwinds, strategic investment in vertical integration and modular platform design offers a pathway to resilience. By internalizing key production steps-such as antibody conjugation or nucleic acid library preparation-firms can cushion the impact of external levies. Additionally, collaborative consortia among diagnostic developers aim to pool resources for tariff-averse reagent procurement, preserving affordability for end users while sustaining innovation.

Comprehensive Segmentation Perspectives Across the Diagnostic Value Chain

A granular examination of market segmentation reveals the extensive breadth of diagnostic modalities, biomarker classes and end users shaping this domain. In terms of test type, laboratory-based platforms continue to anchor the market, supported by established biomarker testing workflows, enzyme-linked immunosorbent assays and sophisticated immunoassay techniques. Nevertheless, point-of-care alternatives-characterized by portable analyzers and rapid diagnostic tests-are gaining traction among outpatient clinics and community health settings.

When exploring biomarker types, genetic markers such as Apolipoprotein E variants and PSEN1/PSEN2 mutations provide vital insights into hereditary risk profiles, whereas metabolic signatures from lipidomic changes and broader metabolomic panels capture dynamic disease biology. Protein markers remain a cornerstone, with quantification of beta-amyloid peptides, tau species and neurofilament light chains delivering robust correlations to neurodegeneration.

End-user analysis highlights diversified adoption across academic and research institutions-spanning gerontology and neuroscience departments-as well as diagnostic laboratories that balance general pathology services with specialized neurodiagnostics. Hospitals and clinics, from primary care offices to tertiary centers, integrate diagnostic testing into clinical pathways for differential and early diagnosis.

Further stratification by application underscores an equilibrium between clinical diagnosis, drug development and fundamental research. Differential diagnosis and early detection assays support patient management, while clinical trial biomarker panels and target validation studies underpin pharmaceutical pipelines. In parallel, research-driven biomarker discovery and pathophysiological investigations continue to refine our understanding of disease mechanisms.

On the technology front, mass spectrometry platforms-including gas and liquid chromatography-mass spectrometry systems-deliver unparalleled analytical depth, even as multiplex assay technologies like Luminex and microarray chips offer high-throughput profiling. Next-generation sequencing panels, encompassing both DNA and RNA workflows, expand the molecular portrait of Alzheimer’s pathology. Finally, staging insights differentiate confirmed Alzheimer’s disease, mild cognitive impairment and preclinical cohorts, with applications ranging from progression assessment and therapeutic monitoring to predictive testing and risk evaluation.

Key Regional Dynamics Influencing Market Uptake

Regional dynamics play a pivotal role in shaping the accessibility and deployment of Alzheimer’s blood tests. In the Americas, established healthcare infrastructure and reimbursement frameworks accelerate adoption in both clinical diagnosis and research settings, yet disparities in rural and underserved communities underscore the need for scalable point-of-care solutions. Transitioning northward, regulatory agencies have exhibited progressive policies for biomarker qualification, fostering commercial growth and cross-border collaborations.

Across Europe, Middle East and Africa, heterogeneous markets present a mosaic of challenges and opportunities. Western European nations benefit from centralized health systems and robust research funding, whereas emerging economies in the Middle East and Africa grapple with infrastructure gaps and budget constraints. Nonetheless, public-private partnerships are catalyzing diagnostic outreach programs, while pan-regional consortia aim to harmonize technical standards and streamline cross-market validations.

In Asia-Pacific, rapid economic development and increasing healthcare investments are fueling demand for early detection tools. Governments are prioritizing dementia care within national health agendas, leading to expanded screening initiatives and pilot programs that leverage portable analyzers. Local manufacturers are also ramping up production capacity, introducing cost-effective assay kits tailored to regional biomarker profiles and patient demographics.

Strategic Movements Among Leading Diagnostic Innovators

Leading organizations are deploying diverse strategies to consolidate their positions in this competitive landscape. Abcam Plc has expanded its portfolio of high-affinity antibodies and assay kits, while AlzPath, Inc. focuses on proprietary multiplex platforms designed for streamlined clinical workflows. Amoneta Diagnostics pursues a precision medicine approach, integrating genetic and proteomic data to deliver tailored diagnostic reports. C2N Diagnostics distinguishes itself through ultrasensitive immunoassays that detect neurodegenerative markers at subfemtomolar levels.

Diadem SpA leverages mass spectrometry expertise to offer comprehensive biomarker panels, whereas Eli Lilly and Company and Genentech, Inc. invest in companion diagnostic development to support their Alzheimer’s therapeutic pipelines. IngenioRx, Inc. collaborates with payers and providers to optimize reimbursement pathways, and Jesseniya Impulse IT Solutions Pvt Ltd enhances data integration and digital reporting for seamless clinical adoption.

Olink Proteomics and Quanterix Corporation have introduced multiplex and single-molecule array technologies respectively, driving sensitivity and throughput. Quest Diagnostics Incorporated and Roche Diagnostics deliver end-to-end laboratory services, from sample collection to result interpretation, while Siemens Healthineers AG integrates advanced imaging and blood-based assays into holistic diagnostic solutions. Together, these players are forging strategic alliances, pursuing M&A opportunities and investing in digital platforms to strengthen their competitive edge.

Actionable Recommendations for Stakeholders to Accelerate Adoption

Leaders seeking to capitalize on the blood-based Alzheimer’s testing market should prioritize the following actions. First, invest in platform modularity that allows rapid incorporation of emerging biomarkers without overhauling existing infrastructure. This will enable swift responses to scientific breakthroughs and regulatory approvals. Second, establish multifaceted partnerships spanning academic institutions, pharmaceutical developers and technology providers to create integrated diagnostic ecosystems that support both clinical care and drug development.

Third, develop tiered product offerings that address distinct end-user needs-from high-throughput laboratory assays for research centers to compact point-of-care devices for community clinics. Leveraging scalable manufacturing and localized supply chains can mitigate tariff impacts and reduce time to market. Fourth, engage proactively with regulatory bodies to shape biomarker qualification guidelines and expedite approvals, ensuring alignment between assay validation studies and clinical requirements.

Finally, bolster digital health initiatives by integrating test results with electronic health records, telemedicine platforms and predictive analytics. Such connectivity enhances longitudinal patient monitoring, facilitates real-world evidence generation and elevates the perceived value of blood-based diagnostics among payers and providers.

Conclusion: Unifying Innovation for Enhanced Patient Outcomes

The convergence of advanced assay technologies, regulatory momentum and stakeholder collaboration has propelled blood tests into the forefront of Alzheimer’s diagnostics. By synthesizing genetic, metabolic and proteomic markers within versatile platforms, the industry is redefining early detection, guiding therapeutic interventions and deepening our understanding of neurodegenerative processes.

Looking ahead, continued innovation in assay sensitivity, point-of-care deployment and digital integration will be essential. Moreover, adaptive strategies to navigate tariff challenges and region-specific dynamics will shape market trajectories. Ultimately, success will hinge on cohesive partnerships that align clinical imperatives, research priorities and commercial objectives to deliver meaningful impact for patients and healthcare systems alike.

Market Segmentation & Coverage

This research report categorizes the Blood Tests for Alzheimer's Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Laboratory
    • Biomarker Testing
    • ELISA
    • Immunoassay
  • Point of Care
    • Portable Analyzers
    • Rapid Diagnostic Tests
  • Genetic Markers
    • Apolipoprotein E (ApoE)
    • PSEN1/PSEN2 Mutations
  • Metabolic Markers
    • Lipidomic Changes
    • Metabolomics
  • Protein Markers
    • Beta-Amyloid
    • Neurofilament Light Chains
    • Tau
  • Academic & Research Institutions
    • Departments of Gerontology
    • Neuroscience Research Departments
  • Diagnostic Laboratories
    • General Pathology
    • Specialized Diagnostics
  • Hospitals & Clinics
    • Primary Care Facilities
    • Tertiary Care Centers
  • Clinical Diagnosis
    • Differential Diagnosis
    • Early Diagnosis
  • Drug Development
    • Clinical Trials
    • Target Validation
  • Research
    • Biomarker Discovery
    • Pathophysiological Studies
  • Mass Spectrometry
    • GC-MS
    • LC-MS
  • Multiplex Assay
    • Luminex Technology
    • Microarray
  • Next-Generation Sequencing
    • DNA Sequencing
    • RNA Sequencing
  • Confirmed Alzheimer's Disease
    • Disease Progression Assessment
    • Therapeutic Monitoring
  • Mild Cognitive Impairment
    • Confirmatory Testing
    • Progress Monitoring
  • Pre-Clinical Stage
    • Predictive Testing
    • Risk Assessment Testing

This research report categorizes the Blood Tests for Alzheimer's Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Blood Tests for Alzheimer's Diagnosis Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abcam Plc
  • AlzPath, Inc.
  • Amoneta Diagnostics
  • C2N Diagnostics
  • Diadem SpA
  • Eli Lilly and Company
  • Genentech, Inc.
  • IngenioRx, Inc.
  • Jesseniya Impulse IT Solutions Pvt Ltd
  • Olink Proteomics
  • Quanterix Corporation
  • Quest Diagnostics Incorporated
  • Roche Diagnostics
  • Siemens Healthineers AG

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Blood Tests for Alzheimer's Diagnosis Market, by Test Type
8.1. Introduction
8.2. Laboratory
8.2.1. Biomarker Testing
8.2.2. ELISA
8.2.3. Immunoassay
8.3. Point of Care
8.3.1. Portable Analyzers
8.3.2. Rapid Diagnostic Tests
9. Blood Tests for Alzheimer's Diagnosis Market, by Biomarker Type
9.1. Introduction
9.2. Genetic Markers
9.2.1. Apolipoprotein E (ApoE)
9.2.2. PSEN1/PSEN2 Mutations
9.3. Metabolic Markers
9.3.1. Lipidomic Changes
9.3.2. Metabolomics
9.4. Protein Markers
9.4.1. Beta-Amyloid
9.4.2. Neurofilament Light Chains
9.4.3. Tau
10. Blood Tests for Alzheimer's Diagnosis Market, by End User
10.1. Introduction
10.2. Academic & Research Institutions
10.2.1. Departments of Gerontology
10.2.2. Neuroscience Research Departments
10.3. Diagnostic Laboratories
10.3.1. General Pathology
10.3.2. Specialized Diagnostics
10.4. Hospitals & Clinics
10.4.1. Primary Care Facilities
10.4.2. Tertiary Care Centers
11. Blood Tests for Alzheimer's Diagnosis Market, by Application
11.1. Introduction
11.2. Clinical Diagnosis
11.2.1. Differential Diagnosis
11.2.2. Early Diagnosis
11.3. Drug Development
11.3.1. Clinical Trials
11.3.2. Target Validation
11.4. Research
11.4.1. Biomarker Discovery
11.4.2. Pathophysiological Studies
12. Blood Tests for Alzheimer's Diagnosis Market, by Test Method Technology
12.1. Introduction
12.2. Mass Spectrometry
12.2.1. GC-MS
12.2.2. LC-MS
12.3. Multiplex Assay
12.3.1. Luminex Technology
12.3.2. Microarray
12.4. Next-Generation Sequencing
12.4.1. DNA Sequencing
12.4.2. RNA Sequencing
13. Blood Tests for Alzheimer's Diagnosis Market, by Stage of Alzheimer's
13.1. Introduction
13.2. Confirmed Alzheimer's Disease
13.2.1. Disease Progression Assessment
13.2.2. Therapeutic Monitoring
13.3. Mild Cognitive Impairment
13.3.1. Confirmatory Testing
13.3.2. Progress Monitoring
13.4. Pre-Clinical Stage
13.4.1. Predictive Testing
13.4.2. Risk Assessment Testing
14. Americas Blood Tests for Alzheimer's Diagnosis Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Blood Tests for Alzheimer's Diagnosis Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Blood Tests for Alzheimer's Diagnosis Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abcam Plc
17.3.2. AlzPath, Inc.
17.3.3. Amoneta Diagnostics
17.3.4. C2N Diagnostics
17.3.5. Diadem SpA
17.3.6. Eli Lilly and Company
17.3.7. Genentech, Inc.
17.3.8. IngenioRx, Inc.
17.3.9. Jesseniya Impulse IT Solutions Pvt Ltd
17.3.10. Olink Proteomics
17.3.11. Quanterix Corporation
17.3.12. Quest Diagnostics Incorporated
17.3.13. Roche Diagnostics
17.3.14. Siemens Healthineers AG
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET MULTI-CURRENCY
FIGURE 2. BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET MULTI-LANGUAGE
FIGURE 3. BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APOLIPOPROTEIN E (APOE), BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PSEN1/PSEN2 MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LIPIDOMIC CHANGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLOMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BETA-AMYLOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEUROFILAMENT LIGHT CHAINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TAU, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DEPARTMENTS OF GERONTOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEUROSCIENCE RESEARCH DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENERAL PATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY SPECIALIZED DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRIMARY CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY EARLY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PATHOPHYSIOLOGICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GC-MS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LC-MS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MULTIPLEX ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LUMINEX TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MULTIPLEX ASSAY, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMED ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DISEASE PROGRESSION ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMED ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROGRESS MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRE-CLINICAL STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RISK ASSESSMENT TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRE-CLINICAL STAGE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MULTIPLEX ASSAY, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMED ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRE-CLINICAL STAGE, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MULTIPLEX ASSAY, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMED ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRE-CLINICAL STAGE, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MULTIPLEX ASSAY, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMED ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRE-CLINICAL STAGE, 2018-2030 (USD MILLION)
TABLE 152. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 153. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 154. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 155. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 156. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 157. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, 2018-2030 (USD MILLION)
TABLE 158. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 159. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 161. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 162. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 163. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 165. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 166. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 167. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 168. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 169. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MULTIPLEX ASSAY, 2018-2030 (USD MILLION)
TABLE 170. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 171. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2018-2030 (USD MILLION)
TABLE 172. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMED ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 173. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, 2018-2030 (USD MILLION)
TABLE 174. CANADA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRE-CLINICAL STAGE, 2018-2030 (USD MILLION)
TABLE 175. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 176. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 177. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 178. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 179. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, 2018-2030 (USD MILLION)
TABLE 181. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 184. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 185. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 186. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 188. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 189. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 190. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 192. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MULTIPLEX ASSAY, 2018-2030 (USD MILLION)
TABLE 193. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 194. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2018-2030 (USD MILLION)
TABLE 195. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMED ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 196. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, 2018-2030 (USD MILLION)
TABLE 197. MEXICO BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRE-CLINICAL STAGE, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MULTIPLEX ASSAY, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMED ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRE-CLINICAL STAGE, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MULTIPLEX ASSAY, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMED ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRE-CLINICAL STAGE, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CLINICAL DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST METHOD TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MULTIPLEX ASSAY, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY STAGE OF ALZHEIMER'S, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY CONFIRMED ALZHEIMER'S DISEASE, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PRE-CLINICAL STAGE, 2018-2030 (USD MILLION)
TABLE 269. CHINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 270. CHINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY LABORATORY, 2018-2030 (USD MILLION)
TABLE 271. CHINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 272. CHINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 273. CHINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY GENETIC MARKERS, 2018-2030 (USD MILLION)
TABLE 274. CHINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY METABOLIC MARKERS, 2018-2030 (USD MILLION)
TABLE 275. CHINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY PROTEIN MARKERS, 2018-2030 (USD MILLION)
TABLE 276. CHINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. CHINA BLOOD TESTS FOR ALZHEIMER'S DIAGNOSIS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2030 (USD MILLI

Companies Mentioned

  • Abcam Plc
  • AlzPath, Inc.
  • Amoneta Diagnostics
  • C2N Diagnostics
  • Diadem SpA
  • Eli Lilly and Company
  • Genentech, Inc.
  • IngenioRx, Inc.
  • Jesseniya Impulse IT Solutions Pvt Ltd
  • Olink Proteomics
  • Quanterix Corporation
  • Quest Diagnostics Incorporated
  • Roche Diagnostics
  • Siemens Healthineers AG

Methodology

Loading
LOADING...

Related Topics

Related Reports

Alzheimer'S Disease Diagnostics Market Size, Share & Trends Analysis Report by Diagnostics Technique (Biomarkers, Imaging Techniques, Genetic Testing), Type (Triage, Diagnosis, Screening), End-Use, and Region with Growth Forecasts, 2025-2030 - Product Image

Alzheimer'S Disease Diagnostics Market Size, Share & Trends Analysis Report by Diagnostics Technique (Biomarkers, Imaging Techniques, Genetic Testing), Type (Triage, Diagnosis, Screening), End-Use, and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Rivastigmine Hydrogen Tartrate Capsules Market - Global Forecast to 2030 - Product Image

Rivastigmine Hydrogen Tartrate Capsules Market - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Alzheimer's Disease Diagnostics & Therapeutics Market by Product (Diagnostics, Therapeutics), Patient Demographics (65-74 Years, 75-84 Years, Above 85 Years), Disease Stage, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Alzheimer's Disease Diagnostics & Therapeutics Market by Product (Diagnostics, Therapeutics), Patient Demographics (65-74 Years, 75-84 Years, Above 85 Years), Disease Stage, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets - Product Image

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

  • Report
  • 125 Pages
  • Global
From
Alzheimer's Disease Diagnostic - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Alzheimer's Disease Diagnostic - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.